

Comparison of different treatments in the management of recurrent herpes labialis

Submission date 25/08/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 04/09/2023	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 21/01/2025	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Recurrent herpes labialis results from reactivation of the latent herpes simplex type 1 virus. The injury is characterized by redness of the skin (erythema) and a small raised area of skin of papule that turns into vesicles filled with fluid rich in viral particles. Subsequently, these vesicles rupture, leading to ulceration and eventual crusting, initial symptoms precede these lesions in 46-60% of instances, and the healing process lasts between 10-8 days. This study aims to evaluate the effectiveness of low-level laser and olive leaf extract in the management of recurrent herpes labialis by comparing each treatment with acyclovir (the standard treatment).

Who can participate?

Patients aged over 18 years old who have a herpes labialis lesion in the vesicular stage

What does the study involve?

The patient sample will be randomly distributed among the groups according to the treatment method used:

Group 1 (the control group): (n = 20) application of topical acyclovir (Veramid 5%), 5 times/ 5 days, with the application of an inactive laser

Group 2: (n=20) application of diode laser (650 nm,100 mW) on the first day and after 48 hours, in addition to placebo cream

Group 3: (n=20) treatment with olive leaf extract in the form of a combined emollient and gel (emolgel), 5 times/ 5 days, with the application of an inactive laser.

What are the possible benefits and risks of participating?

The benefits of this study are the results that investigate safer alternatives to traditional antivirals for the management of recurrent herpes labialis. There are no possible risks of participating, only that it is possible that accelerated healing and rapid pain relief do not occur.

Where is the study run from?

Damascus University (Syria)

When is the study starting and how long is it expected to run for?

June 2021 to January 2024

Who is funding the study?
Damascus University – Funder No. 501100020595 (Syria)

Who is the main contact?
Mai Gaizeh Al-Hallak, memogh.1995mai@gmail.com

Contact information

Type(s)

Principal investigator

Contact name

Dr Mai Gaizeh Al-Hallak

Contact details

Mazzeh Street
Damascus
Syria
00963
+963 935423239
memogh.1995mai@gmail.com

Type(s)

Principal investigator

Contact name

Dr Mai Gaizeh Al-Hallak

Contact details

Mazzeh street
Damascus
Syria
00963
+963 935423239
maighallak@gmail.com

Type(s)

Principal investigator

Contact name

Prof Abeer Aljoujou

Contact details

Al mazzeh
Damascus
Syria
00963
+963 944703131
abeerjoujou@gmail.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

2640

Study information

Scientific Title

A comparative study between low-level laser therapy (LLLT) and olive leaf extract (OLE) in the management of recurrent herpes labialis (RHL)

Study objectives

Current study hypothesis 21/01/2025:

For the pain variable:

1. Null hypothesis H0: There are no statistically significant differences in the effectiveness of the three treatments used in the studied groups.
2. Alternative Hypothesis H1: There are statistically significant differences in the effectiveness of the three treatments used in the studied groups.

For the healing speed variable:

1. Null hypothesis H0: No statistically significant differences exist in the effectiveness of the three treatments used in the studied groups.
2. Alternative Hypothesis H1: There are statistically significant differences in the effectiveness of the three treatments used in the studied groups.

Previous study hypothesis:

For the pain variable:

1. Null hypothesis H0: There are no statistically significant differences in the effectiveness of the four treatments used in the studied groups.
2. Alternative Hypothesis H1: There are statistically significant differences in the effectiveness of the four treatments used in the studied groups.

For the healing speed variable:

1. Null hypothesis H0: No statistically significant differences exist in the effectiveness of the four treatments used in the studied groups.
2. Alternative Hypothesis H1: There are statistically significant differences in the effectiveness of the four treatments used in the studied groups.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 02/08/2021, Scientific Research Council (Baramkeh, Damascus, 00963, Syria; +9693935423239; info@damascusuniversity.edu.sy), ref: 2640

Study design

Randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment, Efficacy

Health condition(s) or problem(s) studied

Patients with recurrent herpes labialis

Interventions

Current interventions as of 14/01/2025:

This is a randomized controlled clinical study in which the patient sample will be divided into three equal groups according to the method of treatment used, and clinical evaluation will be conducted by blinded researchers who do not know of the type of treatment that will be used.

The sample will consist of 60 patients with recurrent herpes labialis in the vesicular stage over the age of 18 who are reviewers of the Department of Oral Medicine at Damascus University. The sample size was calculated using the G-power program.

Sample randomization:

The sample will be distributed among the three groups using an envelope containing 60 cards numbered from 1-3, where the patient takes the card corresponding to the number of the treatment group.

Methodology:

Firstly, written informed consent must first be obtained from the patient after being informed of the aims and methods of the current study. Secondly, patients will be screened to ensure they meet the inclusion criteria, then patients will be randomized into four study groups.

Interventional groups:

Group 1: Drug therapy with acyclovir: A preparation containing acyclovir at a concentration of 5% (Veramid from Medico) will be applied five times daily to the lesion site for 5 days. A placebo laser will also be applied to the site of the lesion of blinding.

Group 2: Low-level laser therapy (LLL) diode LASER (650 nm, 100 mW) will be applied for 120 seconds. The laser will be applied on the first day and 48 hours after the first application. The patient will be given a placebo cream to apply five times for five days.

Group 3: Treatment with olive leaf extract (OLE). The active ingredients will be extracted from the olive leaves by the following method:

1. Dry the olive leaves in the shade, then grind them and keep them in a dark glass container
2. Extraction using 70% ethanol by ultrasound (40°C, 30 minutes)
3. Filter the extracts and then dilute them to 100 ml with distilled water
4. Determination of total phenols by the Follin-Ciocalteu method
5. Introducing the extract into a topical pharmaceutical formulation (Emulgel)

Patients are recommended to apply this preparation 5 times a day for 5 days. In addition, a placebo laser will also be applied to the site of the lesion (on the first day and after 48 hours) for blinding.

There is no follow-up after the lesion has healed.

Previous interventions:

This is a randomized controlled clinical study in which the patient sample will be divided into four equal groups according to the method of treatment used, and clinical evaluation will be conducted by blinded researchers who do not know of the type of treatment that will be used.

The sample will consist of 80 patients with recurrent herpes labialis in the vesicular stage over the age of 18 who are reviewers of the Department of Oral Medicine at Damascus University. The sample size was calculated using the G-power program.

Sample randomization:

The sample will be distributed among the four groups using an envelope containing 80 cards numbered from 1-4, where the patient takes the card corresponding to the number of the treatment group.

Methodology:

Firstly, written informed consent must first be obtained from the patient after being informed of the aims and methods of the current study. Secondly, patients will be screened to ensure they meet the inclusion criteria, then patients will be randomized into four study groups.

Interventional groups:

Group 1: Drug therapy with acyclovir: A preparation containing acyclovir at a concentration of 5% (Veramid from Medico) will be applied five times daily to the lesion site for 5 days. A placebo laser will also be applied to the site of the lesion of blinding.

Group 2: Low-level laser therapy (LLL) diode LASER (650 nm, 100 mW) will be applied for 120 seconds. The laser will be applied on the first day and 48 hours after the first application. The patient will be given a placebo cream to apply five times for five days.

Group 3: Photodynamic therapy (PDT): The area will first be cleaned with a cotton ball soaked in a physiological solution to remove any cosmetic or sunscreen residue. Then the vesicle will be punctured with a sterile needle, to allow the discharge of the contents of the vesicle. The area will be dried using sterile gauze within the boundaries of the lesion without pressure. After that, the photosensitizer (methylene blue 0.01%) will be applied to the herpes lesion with a brush. After 5 minutes low-level laser will be applied (Diode laser 650 nm, 100 mW). Finally, the traces of the photosensitizer will be cleaned with a cotton ball soaked in sterile saline without pressure. The low-level laser without a photosensitizer will be applied 48 hours after the first application and the patient will be given a placebo cream to apply five times for five days.

Group 4: Treatment with olive leaf extract (OLE). The active ingredients will be extracted from the olive leaves by the following method:

1. Dry the olive leaves in the shade, then grind them and keep them in a dark glass container
2. Extraction using 70% ethanol by ultrasound (40°C, 30 minutes)
3. Filter the extracts and then dilute them to 100 ml with distilled water
4. Determination of total phenols by the Follin-Ciocalteu method
5. Introducing the extract into a topical pharmaceutical formulation (Emulgel)

Patients are recommended to apply this preparation 5 times a day for 5 days. In addition, a placebo laser will also be applied to the site of the lesion (on the first day and after 48 hours) for blinding.

There is no follow-up after the lesion has healed.

Intervention Type

Mixed

Primary outcome(s)

The primary outcome measures are assessed at baseline (T0: Before taking any action in the first session) and at the following time points:

1. Pain measured using a visual analogue scale (VAS)
2. Healing speed measured using study records of the day the crust of the lesion falls off spontaneously

T1: After applying the laser (activated or placebo) in the first session

T2: The second session (after 48 hours) before applying the laser (activated or placebo)

T3: The second session after applying the laser (activated or placebo)

T4: Third session after 7 days. The day when the pain has completely disappeared is also recorded.

Key secondary outcome(s)

Pain measured using a VAS on day 7

Completion date

01/01/2024

Eligibility

Key inclusion criteria

1. Good general health
2. 18 years of age or older
3. Recurrent herpes labialis in the vesicular stage
4. Other treatments for the present lesion

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

40

Key exclusion criteria

1. Pregnant and lactating
2. Patients who took antiviral drugs during the four weeks preceding treatment
3. Patients who took anti-inflammatory drugs or antibiotics during the two weeks preceding treatment
4. Diabetes
5. Patients with skin injuries that affect the course of healing or interfere with the results of the study
6. Patients who have allergic reactions to the medications used
7. Immunocompromised patients

Date of first enrolment

01/10/2021

Date of final enrolment

01/12/2023

Locations

Countries of recruitment

Syria

Study participating centre**Damascus University**

Oral Medicine Department, Faculty of Dentistry

Al Mazzeh High Way

Damascus

Syria

00963

Sponsor information

Organisation

Damascus University

ROR

<https://ror.org/03m098d13>

Funder(s)

Funder type

University/education

Funder Name

Damascus University

Alternative Name(s)

University of Damascus, , DU

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

Syria

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and analyzed during the current study will be available on request from Mai Gaizeh Al-Hallak (memogh.1995mai@gmail.com)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/02/2024	21/02/2024	Yes	No
Results article		02/12/2024	03/12/2024	Yes	No
Participant information sheet			04/09/2023	No	Yes
Participant information sheet			04/09/2023	No	Yes
Participant information sheet			04/09/2023	No	Yes